Evogene Ltd
EVGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.85M
Close$
Share Statistics
| Market cap | $4.85 Million |
|---|---|
| Enterprise Value | $-2,382,038.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 0.78 |
| Outstanding Shares | 12,199,883 |
Return
| Return on Equity | 335.26% |
|---|---|
| Return on Assets | -82.07% |
| Return on Invested Capital | -203.83% |
Valuation & Multiples
| P/E Ratio | -0.63 |
|---|---|
| PEG | 1.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.49 |
| Enterprise Value to EBIT | 0.11 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.89 |
| Debt to Equity | -0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$325,000
Average shareholder expectationNext Earnings Call
Expected Date
August 26, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$325,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Evogene Ltd
CEO: Ofer Haviv Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, I...